Article
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2026
Thangavadivel Shanmugapriya, Shaffer Jami, Misra Shrilekha, Benrashid Samon, Gordon Britten K, He Alexander, Li Wantong, Oyman Konur, Chura Annika, Cabrera Shelby, Turkoglu Altan, Lai Tzung-Huei, Rogers Kerry A, Bhat Seema A, Byrd John C, Blachly James S, Woyach Jennifer A, Blaser Bradley W
Abstract excerpt
PURPOSE: The development of Bruton tyrosine kinase inhibitors (BTKi) and their introduction into clinical practice represents a major advance in the treatment of chronic lymphocytic leukemia (CLL). However, monotherapy with ibrutinib or other BTKis does not induce complete remissions or undetectable minimal residual disease even with extended therapy. Therefore, there is a need to understand the differences...
Topics
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
- Adenine
- Piperidines
- RNA-Seq
- Single-Cell Analysis
- Protein Kinase Inhibitors
- Drug Resistance, Neoplasm